KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Short term Debt (2016 - 2025)

Eli Lilly (LLY) has disclosed Short term Debt for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt fell 68.05% year-over-year to $1.6 billion, compared with a TTM value of $1.6 billion through Dec 2025, down 68.05%, and an annual FY2025 reading of $1.6 billion, down 68.05% over the prior year.
  • Short term Debt was $1.6 billion for Q4 2025 at Eli Lilly, roughly flat from $1.6 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $6.9 billion in Q4 2023 and bottomed at $3.1 million in Q1 2023.
  • Average Short term Debt over 5 years is $2.4 billion, with a median of $1.7 billion recorded in 2022.
  • The sharpest move saw Short term Debt crashed 99.85% in 2021, then soared 53174.19% in 2024.
  • Year by year, Short term Debt stood at $1.5 billion in 2021, then dropped by 2.42% to $1.5 billion in 2022, then skyrocketed by 359.96% to $6.9 billion in 2023, then dropped by 25.89% to $5.1 billion in 2024, then tumbled by 68.05% to $1.6 billion in 2025.
  • Business Quant data shows Short term Debt for LLY at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $5.7 billion in Q2 2025.